Justin Chakma - Jan 2, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Business Officer
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:41 PM
Previous filing
Jan 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +350K $0.00 350K Jan 2, 2024 Common Stock 350K $5.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.